Spatial transcriptomic analysis of Sonic hedgehog medulloblastoma identifies that the loss of heterogeneity and promotion of differentiation underlies the response to CDK4/6 inhibition.
CDK4/6 inhibitor
Medulloblastoma
Neuron differentiation
Palbociclib
Relapse
Spatial transcriptomics
Visium
Journal
Genome medicine
ISSN: 1756-994X
Titre abrégé: Genome Med
Pays: England
ID NLM: 101475844
Informations de publication
Date de publication:
01 05 2023
01 05 2023
Historique:
received:
06
07
2022
accepted:
20
04
2023
medline:
3
5
2023
pubmed:
2
5
2023
entrez:
1
5
2023
Statut:
epublish
Résumé
Medulloblastoma (MB) is a malignant tumour of the cerebellum which can be classified into four major subgroups based on gene expression and genomic features. Single-cell transcriptome studies have defined the cellular states underlying each MB subgroup; however, the spatial organisation of these diverse cell states and how this impacts response to therapy remains to be determined. Here, we used spatially resolved transcriptomics to define the cellular diversity within a sonic hedgehog (SHH) patient-derived model of MB and show that cells specific to a transcriptional state or spatial location are pivotal for CDK4/6 inhibitor, Palbociclib, treatment response. We integrated spatial gene expression with histological annotation and single-cell gene expression data from MB, developing an analysis strategy to spatially map cell type responses within the hybrid system of human and mouse cells and their interface within an intact brain tumour section. We distinguish neoplastic and non-neoplastic cells within tumours and from the surrounding cerebellar tissue, further refining pathological annotation. We identify a regional response to Palbociclib, with reduced proliferation and induced neuronal differentiation in both treated tumours. Additionally, we resolve at a cellular resolution a distinct tumour interface where the tumour contacts neighbouring mouse brain tissue consisting of abundant astrocytes and microglia and continues to proliferate despite Palbociclib treatment. Our data highlight the power of using spatial transcriptomics to characterise the response of a tumour to a targeted therapy and provide further insights into the molecular and cellular basis underlying the response and resistance to CDK4/6 inhibitors in SHH MB.
Sections du résumé
BACKGROUND
Medulloblastoma (MB) is a malignant tumour of the cerebellum which can be classified into four major subgroups based on gene expression and genomic features. Single-cell transcriptome studies have defined the cellular states underlying each MB subgroup; however, the spatial organisation of these diverse cell states and how this impacts response to therapy remains to be determined.
METHODS
Here, we used spatially resolved transcriptomics to define the cellular diversity within a sonic hedgehog (SHH) patient-derived model of MB and show that cells specific to a transcriptional state or spatial location are pivotal for CDK4/6 inhibitor, Palbociclib, treatment response. We integrated spatial gene expression with histological annotation and single-cell gene expression data from MB, developing an analysis strategy to spatially map cell type responses within the hybrid system of human and mouse cells and their interface within an intact brain tumour section.
RESULTS
We distinguish neoplastic and non-neoplastic cells within tumours and from the surrounding cerebellar tissue, further refining pathological annotation. We identify a regional response to Palbociclib, with reduced proliferation and induced neuronal differentiation in both treated tumours. Additionally, we resolve at a cellular resolution a distinct tumour interface where the tumour contacts neighbouring mouse brain tissue consisting of abundant astrocytes and microglia and continues to proliferate despite Palbociclib treatment.
CONCLUSIONS
Our data highlight the power of using spatial transcriptomics to characterise the response of a tumour to a targeted therapy and provide further insights into the molecular and cellular basis underlying the response and resistance to CDK4/6 inhibitors in SHH MB.
Identifiants
pubmed: 37127652
doi: 10.1186/s13073-023-01185-4
pii: 10.1186/s13073-023-01185-4
pmc: PMC10150495
doi:
Substances chimiques
CDK4 protein, human
EC 2.7.11.22
Cyclin-Dependent Kinase 4
EC 2.7.11.22
Hedgehog Proteins
0
Cyclin-Dependent Kinase 6
EC 2.7.11.22
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
29Informations de copyright
© 2023. The Author(s).
Références
BMC Bioinformatics. 2005 Jun 08;6:144
pubmed: 15941488
Nat Rev Dis Primers. 2019 Feb 14;5(1):11
pubmed: 30765705
Sci Immunol. 2019 Jul 12;4(37):
pubmed: 31300479
Genome Biol. 2019 Dec 23;20(1):296
pubmed: 31870423
Lab Invest. 2020 Sep;100(9):1208-1222
pubmed: 32457352
Acta Neuropathol. 2012 Apr;123(4):473-84
pubmed: 22358457
Cell Syst. 2015 Dec 23;1(6):417-425
pubmed: 26771021
Clin Cancer Res. 2015 Mar 15;21(6):1258-66
pubmed: 25770293
Nature. 2019 Aug;572(7767):74-79
pubmed: 31341285
Cancer Cell. 2016 Apr 11;29(4):508-522
pubmed: 27050100
EMBO J. 2021 Jul 15;40(14):e105712
pubmed: 34057742
Cell. 2021 Oct 28;184(22):5577-5592.e18
pubmed: 34644529
Nature. 2019 Aug;572(7767):67-73
pubmed: 31043743
Nat Commun. 2021 Nov 1;12(1):6278
pubmed: 34725363
Genome Med. 2023 May 1;15(1):29
pubmed: 37127652
Nat Immunol. 2019 Feb;20(2):163-172
pubmed: 30643263
Cancer Cell. 2017 Jun 12;31(6):737-754.e6
pubmed: 28609654
Nature. 2014 Jun 26;510(7506):537-41
pubmed: 24847876
Mol Cell Neurosci. 2021 Sep;115:103650
pubmed: 34197921
Innovation (Camb). 2021 Jul 01;2(3):100141
pubmed: 34557778
J Neuropathol Exp Neurol. 2006 Feb;65(2):176-86
pubmed: 16462208
NPJ Breast Cancer. 2018 Nov 28;4:38
pubmed: 30511015
Clin Cancer Res. 2018 Nov 1;24(21):5250-5260
pubmed: 30021908
Bioinformatics. 2005 Aug 1;21(15):3201-12
pubmed: 15914541
Nature. 2020 May;581(7808):303-309
pubmed: 32214235
Cell Metab. 2021 Sep 7;33(9):1869-1882.e6
pubmed: 34380013
Nature. 2007 Jan 11;445(7124):168-76
pubmed: 17151600
J Clin Oncol. 2011 Apr 10;29(11):1408-14
pubmed: 20823417
Elife. 2020 Feb 14;9:
pubmed: 32057296
Bioinformatics. 2022 May 26;38(11):3151-3153
pubmed: 35485743
Neuropathol Appl Neurobiol. 2021 Aug;47(5):640-652
pubmed: 33368549
Pediatr Neonatol. 2014 Apr;55(2):150-3
pubmed: 23597542
Genome Biol. 2018 Feb 6;19(1):15
pubmed: 29409532
Cell. 2021 Jun 24;184(13):3573-3587.e29
pubmed: 34062119
Cancer Cell. 2019 Sep 16;36(3):302-318.e7
pubmed: 31474569
Lancet Oncol. 2006 Oct;7(10):813-20
pubmed: 17012043
Biostatistics. 2017 Jul 1;18(3):451-464
pubmed: 28334062
Nature. 2017 Jul 19;547(7663):311-317
pubmed: 28726821
PLoS One. 2018 Feb 5;13(2):e0191629
pubmed: 29401521
Nature. 2012 Aug 2;488(7409):100-5
pubmed: 22832583
Front Neural Circuits. 2021 Jan 15;14:611841
pubmed: 33519389
J Biol Chem. 2004 Dec 17;279(51):53491-7
pubmed: 15466411
Sci Rep. 2017 Dec 4;7(1):16878
pubmed: 29203879
Brain Res Rev. 2011 Jan 7;66(1-2):220-45
pubmed: 20937306
Front Cell Neurosci. 2020 Aug 06;14:198
pubmed: 32848611
Clin Cancer Res. 2021 Dec 1;27(23):6529-6542
pubmed: 34385296
Genome Biol. 2010;11(3):R25
pubmed: 20196867
Curr Opin Oncol. 2013 Nov;25(6):674-81
pubmed: 24076581
Cell. 2020 Feb 6;180(3):502-520.e19
pubmed: 31983537
Neurooncol Adv. 2020 Feb 24;2(1):vdaa021
pubmed: 32642682
PLoS One. 2017 Jun 28;12(6):e0179347
pubmed: 28658323
J Clin Oncol. 2005 Nov 1;23(31):7951-7
pubmed: 16258095
J Exp Med. 2021 Aug 2;218(9):
pubmed: 34254999
PLoS Comput Biol. 2012;8(12):e1002790
pubmed: 23284274
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Brain Pathol. 2007 Apr;17(2):151-64
pubmed: 17388946
Genome Biol. 2014 Feb 03;15(2):R29
pubmed: 24485249
Clin Cancer Res. 2017 Oct 1;23(19):5802-5813
pubmed: 28637687
Oncogene. 2017 Jun 29;36(26):3749-3759
pubmed: 28218903
Cancer Cell. 2015 Jan 12;27(1):72-84
pubmed: 25533335
Nature. 2016 Feb 4;530(7588):57-62
pubmed: 26814967
Nature. 2019 Sep;573(7775):539-545
pubmed: 31534222
Genome Biol. 2021 Mar 8;22(1):78
pubmed: 33685491
Cell. 2020 Sep 3;182(5):1341-1359.e19
pubmed: 32763154
Genome Res. 2014 Aug;24(8):1396-410
pubmed: 24904046
Neuro Oncol. 2012 May;14(5):574-83
pubmed: 22459127
Lancet Oncol. 2013 Nov;14(12):1200-7
pubmed: 24140199
Nat Genet. 2017 May;49(5):780-788
pubmed: 28394352
Mol Cancer Ther. 2004 Nov;3(11):1427-38
pubmed: 15542782
J Clin Med. 2020 Mar 11;9(3):
pubmed: 32168822
F1000Res. 2016 Jun 17;5:1408
pubmed: 27441086
Int J Mol Sci. 2020 Jul 28;21(15):
pubmed: 32731618
Bioinformatics. 2009 Mar 15;25(6):765-71
pubmed: 19176553
Neuro Oncol. 2022 Jan 5;24(1):153-165
pubmed: 34272868
Neuro Oncol. 2022 Feb 1;24(2):273-286
pubmed: 34077540
Nat Commun. 2020 Sep 16;11(1):4660
pubmed: 32938908
Cancer Res. 2017 Dec 1;77(23):6692-6703
pubmed: 28986380
Nucleic Acids Res. 2019 Jan 8;47(D1):D330-D338
pubmed: 30395331
Nat Commun. 2021 Aug 12;12(1):4906
pubmed: 34385456
Nat Med. 2018 Nov;24(11):1752-1761
pubmed: 30349086
Nat Methods. 2012 Jul;9(7):671-5
pubmed: 22930834
Nat Cancer. 2021 Jan;2(1):34-48
pubmed: 33997789
J Neuropathol Exp Neurol. 2000 Apr;59(4):333-7
pubmed: 10759189
Neuro Oncol. 2021 May 5;23(5):732-742
pubmed: 33258962
Glia. 2018 Feb;66(2):221-238
pubmed: 29134703
J Clin Oncol. 2006 Sep 1;24(25):4202-8
pubmed: 16943538
Acta Neuropathol. 2019 Aug;138(2):309-326
pubmed: 31076851
Cerebellum. 2020 Apr;19(2):286-308
pubmed: 32002802
Trends Biotechnol. 2022 Jun;40(6):647-676
pubmed: 34972597